Most positive tests for RSV so far this season in Canada have been among the youngest, federal data suggests. And while ...

In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...

Research led by the CDC and conducted at seven academic pediatric medical centers in the United States finds nirsevimab (sold ...

A briefing document from the Food and Drug Administration (FDA) says that enrollment for all clinical studies of vaccines for ...

New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...

The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...

Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...

Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children,” published in the November 2024 ...

As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But new ...

Nirsevimab (Beyfortus), an antibody targeting respiratory syncytial virus (RSV), is indicated for newborns and infants to prevent bronchiolitis. Available since September 2023, its widespread use ...

The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...